Rolapitant (Varuby®)

Assessment Status Rapid Review Complete
HTA ID -
Drug Rolapitant
Brand Varuby®
Indication For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
Assessment Process
Rapid review commissioned 15/05/2017
Rapid review completed 12/06/2017
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended